Fig. 3From: PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression a Heterogeneity of PIK3CA mutations in two pure classic lobular carcinoma in situ (pure-cLCIS) samples; b heterogeneity of ERBB2 mutation within the LCIS component but not in invasive lobular carcinoma (ILC); c heterozygous and homozygous PIK3CA mutations in invasive cLCIS associated with ILC (inv-cLCIS)Back to article page